Drugs / Nucresiran
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07223203 | Dec 2025 → Dec 2027 expected | familial amyloid neuropathy | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07052903 | Jul 2025 → May 2030 expected | — | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Alnylam Pharmaceuticals | Regulatory Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress alnylam.com ↗
Alnylam announces today that nucresiran has received Fast Track Designation from the FDA's Division of Cardiology and Nephrology for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis in adults to reduce mortality, cardiovascular hospitalizations, and urgent heart failure visits. |
| 2024-11-17 | Alnylam Pharmaceuticals | Results Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose alnylam.com ↗
At these doses, peak reduction of mean TTR levels of greater than 96% were achieved by Day 29. |
| 2023-12-13 | Alnylam Pharmaceuticals | Results Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day alnylam.com ↗
In the Phase 1 study in healthy volunteers, single 300 mg doses of ALN-TTRsc04 achieved rapid knockdown with a mean reduction of greater than 90% at Day 15. |
| 2021-09-29 | Alnylam Pharmaceuticals | Results Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society alnylam.com ↗
The IKARIA-derived ALN-TTRsc04 molecule also demonstrated comparable potency and durability with an analog of vutrisiran in NHP studies. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Alnylam Pharmaceuticals | Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress alnylam.com ↗ |
| 2024-11-17 | Alnylam Pharmaceuticals | Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose alnylam.com ↗ |
| 2023-12-13 | Alnylam Pharmaceuticals | Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day alnylam.com ↗ |
| 2021-09-29 | Alnylam Pharmaceuticals | Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nucresiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07052903 ↗ |
| Route | Subcutaneous | “Nucresiran 300 mg administered SC q6M” NCT07052903 ↗ |